ReviewFrontiers in endocrinology2019
Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Association of adipokines with major adverse cardiovascular events following acute myocardial infarction: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Pooled it
- Maternal Opioids Downregulate Adiponectin Receptor Signaling and Alter Growth in Offspring: Pilot Study.medRxiv : the preprint server for health sciences · 2026Article
- Maternal opioids downregulate adiponectin receptor signaling and alter growth in offspring: pilot study.Frontiers in pediatrics · 2026Article
- Predicting Metabolic Syndrome Using Supervised Machine Learning: A Multivariate Parameter Approach.International journal of molecular sciences · 2025Article
- Harnessing adiponectin for sepsis: current knowledge, clinical insights and future therapies.Critical care (London, England) · 2025Review
- Adiponectin and Adiponectin Receptors in Atherosclerosis.Endocrine reviews · 2025Review
- Adiponectin suppresses stiffness-dependent, profibrotic activation of lung fibroblasts.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Recent Advances in Pre-Clinical Development of Adiponectin Receptor Agonist Therapies for Duchenne Muscular Dystrophy.Biomedicines · 2024Review
- Regulation and Role of Adiponectin Secretion in Rat Ovarian Granulosa Cells.International journal of molecular sciences · 2024Article
- Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF).Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- Crosstalk between myocardial autophagy and sterile inflammation in the development of heart failure.Autophagy reports · 2024Review
- Interaction between Selected Adipokines and Musculoskeletal and Cardiovascular Systems: A Review of Current Knowledge.International journal of molecular sciences · 2023Review
- Adiponectin - stratification biomarker in diastolic cardiac dysfunction.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Article
- Effects of a 12-week walking intervention on circulating lipid profiles and adipokines in normal weight and abdominal obese female college students.Journal of exercise science and fitness · 2023Article
- The Role of Adiponectin during Pregnancy and Gestational Diabetes.Life (Basel, Switzerland) · 2023Review
- Article
- The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review.Cureus · 2022Review
- The Translation and Commercialisation of Biomarkers for Cardiovascular Disease-A Review.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiometabolic diseases encompass those affecting the heart and vasculature as well as other metabolic problems, such as insulin resistance, diabetes, and non-alcoholic fatty liver disease. These diseases tend to have common risk factors, one of which is impaired adiponectin action. This may be due to reduced bioavailability of the hormone or resistance to its effects on target tissues. A strong negative correlation between adiponectin levels and cardiometabolic diseases has been well-documented and research shown that adiponectin has cardioprotective, insulin sensitizing and direct beneficial metabolic effects. Thus, therapeutic approaches to enhance adiponectin action are widely considered to be desirable. The complexity of adiponectin structure and function has so far made progress in this area less than ideal. In this article we will review the effects and mechanism of action of adiponectin on cardiometabolic tissues, identify scenarios where enhancing adiponectin action would be of clinical value and finally discuss approaches via which this can be achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.